Resistance in hematologic malignancies and cancer /
Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are spe...
Salvato in:
| Altri autori: | , |
|---|---|
| Natura: | Elettronico eBook |
| Lingua: | inglese |
| Pubblicazione: |
London, United Kingdom :
Academic Press,
[2025]
|
| Serie: | Cancer sensitizing agents for chemotherapy ;
volume 22 |
| Soggetti: | |
| Accesso online: | ScienceDirect |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | on1468505649 | ||
| 003 | OCoLC | ||
| 005 | 20260915095215.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 241112s2025 enk o 000 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d OCLCO |d OCLCL |d SFB |d OCLCF |d OCLCO | ||
| 020 | |z 9780443217906 | ||
| 035 | |a (OCoLC)1468505649 | ||
| 050 | 4 | |a RC271.C5 | |
| 082 | 0 | 4 | |a 616.99/4061 |2 23/eng/20241112 |1 https://id.oclc.org/worldcat/ddc/E3xHPfT4KgyfbFF6fKcRyx6WPM |
| 245 | 0 | 0 | |a Resistance in hematologic malignancies and cancer / |c edited by Lucia Messingerova, Albert Breier. |
| 264 | 1 | |a London, United Kingdom : |b Academic Press, |c [2025] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer sensitizing agents for chemotherapy ; |v volume 22 | |
| 520 | |a Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise. | ||
| 500 | |a Includes index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (ScienceDirect, viewed November 12, 2024). | |
| 505 | 8 | |a Front Cover -- Resistance in Hematologic Malignancies and Cancer -- Copyright -- Cover Image Insert -- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapyþþ -- About the Series Editor -- Acknowledgments -- Aims and Scope of Volume -- Volume Editor Biography -- Preface -- Contents -- Contributors -- Chapter 1: Drug classification for the treatment of hematologic malignancies -- Introduction -- Chemotherapeutic drugs -- Alkylating agents -- Antimetabolites -- Natural alkaloids with antitubulin activity -- Cytotoxic antibiotics -- Fixed-dose combination drugs -- Small-molecule anticancer drugs -- Tyrosine kinase inhibitors -- Multikinase inhibitors -- Phosphatidylinositol 3-kinase inhibitors -- Enzyme inhibitors -- Histone deacetylase inhibitors -- Isocitrate dehydrogenase inhibitors -- Enhancer ofzZeste homolog 2 inhibitor -- DNA and RNA methyltransferases inhibitor -- Smoothed receptor antagonists |7 Generated by AI | |
| 650 | 0 | |a Drug resistance in cancer cells. | |
| 650 | 0 | |a Blood |x Cancer |x Chemotherapy. | |
| 650 | 0 | |a Hematological oncology. | |
| 650 | 2 | |a Drug Resistance, Neoplasm |0 (DNLM)D019008 | |
| 650 | 6 | |a Cellules cancéreuses |x Résistance aux médicaments. |0 (CaQQLa)201-0217335 | |
| 650 | 6 | |a Hématocancérologie. |0 (CaQQLa)201-0282038 | |
| 650 | 7 | |a Drug resistance in cancer cells |2 fast |0 (OCoLC)fst00898703 | |
| 650 | 7 | |a Hematological oncology |2 fast |0 (OCoLC)fst00954902 | |
| 700 | 1 | |a Messingerova, Lucia, |e editor. | |
| 700 | 1 | |a Breier, Albert, |e editor. | |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780443217906 |